The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LCTX | +108.09% | +44.63% | +7.66% | -42% |
| S&P | +16.9% | +95.99% | +14.39% | +1,546% |
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.77M | 96.4% |
| Gross Profit | $2.56M | 109.1% |
| Gross Margin | 92.41% | 5.6% |
| Market Cap | $207.21M | 10.0% |
| Market Cap / Employee | $2.69M | 0.0% |
| Employees | 77 | 2.7% |
| Net Income | -$30.36M | -426.0% |
| EBITDA | -$4.77M | 16.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $42.27M | 42.7% |
| Accounts Receivable | $0.26M | 8.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.11M | -39.8% |
| Short Term Debt | $1.05M | -6.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -42.26% | -19.7% |
| Return On Invested Capital | -31.43% | -2.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.55M | -6.3% |
| Operating Free Cash Flow | -$5.54M | -7.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.50 | 1.43 | 1.27 | 2.62 | 0.85% |
| Price to Sales | 19.61 | 11.66 | 10.68 | 18.99 | -37.63% |
| Price to Tangible Book Value | 15.42 | 10.57 | 4.70 | 9.50 | -23.36% |
| Enterprise Value to EBITDA | -37.74 | -12.93 | -8.68 | -34.77 | 31.52% |
| Return on Equity | -29.9% | -26.2% | -21.4% | -70.1% | 104.34% |
| Total Debt | $2.75M | $2.51M | $2.24M | $2.15M | -27.01% |
LCTX earnings call for the period ending June 30, 2022.
LCTX earnings call for the period ending September 30, 2021.
LCTX earnings call for the period ending June 30, 2021.
LCTX earnings call for the period ending March 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
